Results 161 to 170 of about 34,497 (254)

Spironolactone-Induced Bilateral Gynecomastia in a Patient With Comorbid Conditions. [PDF]

Cureus
Brahmbhatt SV, Jain D.
europepmc   +1 more source

The conducting airways before and after gender‐affirming hormone therapy in transgender individuals

Experimental Physiology, Volume 111, Issue 10, Page 4277-4285, 1 October 2026.
Abstract On average, females have smaller airways than males. The largest discrepancy in airway size occurs during puberty, when endogenous sex hormone concentrations diverge between males and females. Transgender individuals often use gender‐affirming hormone therapy (GAHT) to align physical characteristics with gender identity.
Shalaya Kipp, Andrew H. Ramsook, Alex J. Miller, Samyd S. Bustos, Jorys Martinez‐Jorge, Brian T. Welch, Juan G. Ripoll, Michael J. Joyner   +7 more
wiley   +1 more source

Post-trial provisions: Unblinding after a randomized blinded trial of spironolactone or doxycycline to treat acne in women. [PDF]

J Invest Dermatol
Barbieri JS, Ellenberg SS, Tierney A, Dattilo J, Mason AC, Mason JB, Papadopoulos M, Baez S, Margolis DJ.   +8 more
europepmc   +1 more source

Patterns of spironolactone management following hyperkalemia among hospitalized patients with heart failure and reduced ejection fraction: a retrospective single-center study. [PDF]

Front Med (Lausanne)
Alshammari AS, Bahamdain FO, Alshahrani AM, Kandasamy G, Rabea Mussa Rabea A, Alyamani W, Idris A, Kamfar Y, Almalki M, Alghamdi S, Kanan M, Bifari N, Alsulami S, Alotaibi AS, Elkholy E.   +14 more
europepmc   +1 more source

Spironolactone versus Bicalutamide for Female Pattern Hair Loss: A 24-Month Unicenter Retrospective Comparative Study of Effectiveness and Safety. [PDF]

Dermatol Ther (Heidelb)
Gil-Redondo R, Jimenez-Cauhe J, Imbernon-Moya A, Buendía-Castaño D, Burgos Blasco P, Díaz-Guimaraens B, Domínguez-Santas M, Hermosa-Gelbard Á, Saceda-Corralo D, Vañó-Galván S.   +9 more
europepmc   +1 more source

PRO/CON debate: nonsteroidal versus steroidal mineralocorticoid receptor antagonists in chronic kidney disease: progress, pragmatism, and remaining uncertainties. [PDF]

Clin Kidney J
Agarwal R, Vogt L, Floege J, Zoccali C.
europepmc   +1 more source

Comparative Efficacy of Aldosterone-Related Sodium-Retention Pathway Therapies for Resistant Hypertension: A Drug-Level Network Meta-Analysis of Randomized Controlled Trials. [PDF]

J Clin Hypertens (Greenwich)
Tsou YL, Wang YH, Lin YS, Chen CL.
europepmc   +1 more source

Effects of mineralocorticoid receptor antagonists on coronary microcirculation: a mini-review. [PDF]

Front Cardiovasc Med
Li Y, Zhang Z.
europepmc   +1 more source

Sex-Specific Safety Signals of Finerenone Versus Spironolactone: Insights From the FDA Adverse Event Reporting System. [PDF]

Cureus
Singla A, Singh G, Kaur G, Luthra S, Lodha C, Malik MS, Kalsoom S, Alo MS, Ali SS, Zulqarnain M.   +9 more
europepmc   +1 more source

GPER and EGFR cross-talk highlight aldosterone- and MR antagonist-induced NO production in cultured endothelial cells. [PDF]

Front Pharmacol
Paredes R, Donoso MV, Lagos CF, Cárdenas C, Acuña-Castillo C, Valdes D, Constandil L, Huidobro-Toro JP.   +7 more
europepmc   +1 more source